906 / 1631
Is it possible to reverse the adverse outcomes of ABC DLBCL
with bortezomib?...no
• The nuclear factor-kB (NF-kB)
pathway is constitutively
activated in ABC DLBCL
1
• The proteasome inhibitor
bortezomib is a potent inhibitor
of NF-ĸB
2
; may therefore have
specific utility in non-GCB
DLBCL and overcoming the
negative prognosis associated
with non-GCB phenotype
3,4
53
1
Davis RE et al. J Exp Med.
2001;194(12):1861
-1874.
2
Bu R et al. Leuk Lymphoma. 2014; 55(2):415-424.
3
Ruan J et al. J Clin Oncol. 2011;29(6):690-697.
4
Dunleavy et al. Blood. 2009; 113(24):6069-6076.
Ruan J et al. J Clin Oncol. 2011;29(6):690-697